FDA rais­es ques­tions about Lil­ly's Alzheimer's drug; Ad­comm votes against MD­MA ther­a­py; In­side Wal­mart Health's chal­lenges; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER